Do you view this collaboration as somewhat a validation of the bi-specific antibody technology, in general? Do you think this gives any sort of validation to AFMD's bi-specific antibody technology. (Lindhtu and I seem to be the only ones here interested in AFMD. The stock has seemingly bottomed out.)
Blade, I didn't answer (sooner) because I am no science wiz to give a credible response ... CTMX bispecifics are differentiated from (some others at least) in that they should theoretically have less off-target effects which may be a bigger concern for others. On a related note I've been looking at PIRS which I find very interesting though I don't like the price run up. I was thinking to look at AFMD closer do you have a bull case?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
... CTMX bispecifics are differentiated from (some others at least) in that they should theoretically have less off-target effects which may be a bigger concern for others. On a related note I've been looking at PIRS which I find very interesting though I don't like the price run up. I was thinking to look at AFMD closer do you have a bull case?
